Monograph
N02BG08 - Ziconotide |
Propably not porphyrinogenic |
PNP |
Rationale
Ziconotide is not a substrate, inhibitor of inducer of CYP enzymes.
Risk for gastrointestinal adverse events in the form of nausea, vomiting, diarrhoea, reduced appetite and anorexia motivates vigilance against insufficient intake of food, especially of carbohydrate.
Chemical description
Ziconitide is a peptide.
Therapeutic characteristics
Ziconotide is indicated for the treatment of severe, chronic pain in adults who require intrathecal (IT) analgesia.
Very common side effects that can be potentially porphyrinogenic through reduction in carbohydrate intake and that also can be confused with an acute porphyria attack are nausea and vomiting. Other common side effects are diarrhoea, upper abdominal pain, reduced appetite and anorexia, myalgia and arthralgia.
Metabolism and pharmacokinetics
Ziconotide is expected to be proteolytic cleaved by peptidases and proteases and degraded to peptide fragments and its individual constituent free amino acids. It is not listed as a substrate, inhibitor or inducer of any CYP enzymes.
References
| # | Citation details | PMID |
|---|---|---|
| * | Summary of Product Characteristics | |
| 1. | The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Ziconotide.
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Poland
Luxembourg
Iceland
Finland
Latvia© NAPOS 2024